These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
59 related articles for article (PubMed ID: 9820831)
1. Comorbid survival among elderly male participants of the Canada health survey: relevance to prostate cancer screening and treatment. Eapen L; Villeneuve PJ; Levy IG; Morrison HI Chronic Dis Can; 1998; 19(3):84-90. PubMed ID: 9820831 [TBL] [Abstract][Full Text] [Related]
2. Prostate cancer and prostate-specific antigen (PSA) screening in Austria. Vutuc C; Schernhammer ES; Haidinger G; Waldhör T Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872 [TBL] [Abstract][Full Text] [Related]
3. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals. Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106 [TBL] [Abstract][Full Text] [Related]
4. Predictors of prostate cancer screening among health fair participants. Chiu BC; Anderson JR; Corbin D Public Health; 2005 Aug; 119(8):686-93. PubMed ID: 15949522 [TBL] [Abstract][Full Text] [Related]
5. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening. Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715 [TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. Welch HG; Schwartz LM; Woloshin S J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071 [TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen test use reported in the 2000 National Health Interview Survey. Ross LE; Coates RJ; Breen N; Uhler RJ; Potosky AL; Blackman D Prev Med; 2004 Jun; 38(6):732-44. PubMed ID: 15193893 [TBL] [Abstract][Full Text] [Related]
8. Prostate cancer incidence and survival in relation to education (United States). Steenland K; Rodriguez C; Mondul A; Calle EE; Thun M Cancer Causes Control; 2004 Nov; 15(9):939-45. PubMed ID: 15577296 [TBL] [Abstract][Full Text] [Related]
9. Behavioral associations between prostate and colon cancer screening. Carlos RC; Underwood W; Fendrick AM; Bernstein SJ J Am Coll Surg; 2005 Feb; 200(2):216-23. PubMed ID: 15664097 [TBL] [Abstract][Full Text] [Related]
10. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men. Culp S; Porter M BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868 [TBL] [Abstract][Full Text] [Related]
11. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
12. Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men. Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR Cancer Causes Control; 2008 Feb; 19(1):25-31. PubMed ID: 17906959 [TBL] [Abstract][Full Text] [Related]
13. Glaucoma and survival: the National Health Interview Survey 1986-1994. Lee DJ; Gómez-Marín O; Lam BL; Zheng DD Ophthalmology; 2003 Aug; 110(8):1476-83. PubMed ID: 12917160 [TBL] [Abstract][Full Text] [Related]
14. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. Ulmert D; Serio AM; O'Brien MF; Becker C; Eastham JA; Scardino PT; Björk T; Berglund G; Vickers AJ; Lilja H J Clin Oncol; 2008 Feb; 26(6):835-41. PubMed ID: 18281654 [TBL] [Abstract][Full Text] [Related]
15. Screening for prostate cancer: updated experience from the Tyrol study. Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158 [TBL] [Abstract][Full Text] [Related]
16. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity. Adolfsson J; Tribukait B; Levitt S Eur Urol; 2007 Oct; 52(4):1028-35. PubMed ID: 17467883 [TBL] [Abstract][Full Text] [Related]
17. Demographics and health-related factors of men receiving prostate-specific antigen screening in Utah. Merrill RM Prev Med; 2001 Dec; 33(6):646-52. PubMed ID: 11716662 [TBL] [Abstract][Full Text] [Related]
18. Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. Birim O; Kappetein AP; Bogers AJ Eur J Cardiothorac Surg; 2005 Nov; 28(5):759-62. PubMed ID: 16157485 [TBL] [Abstract][Full Text] [Related]
19. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02. Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM; Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837 [TBL] [Abstract][Full Text] [Related]
20. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]